This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Verastem, Inc.
11/5/2026
Good afternoon and welcome to Veristem Oncology's third quarter 2026 earnings conference call. My name is Didi and I will be your call operator today. Please note this event is being recorded. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. I will now turn the call over to Julissa Viana, Senior Vice President of Corporate Communications, Investor Relations, and Patient Advocacy at Veristem Oncology. Please go ahead.
Thank you, operator. Welcome, everyone, and thank you for joining us today to discuss Veristem's third quarter of 2026 financial results and recent business updates. This afternoon, we issued a press release detailing these results, along with a slide presentation that we will reference during our call today. Both are available on the Investor Relations section of our website. Before we begin, let me point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today we'll be discussing certain non-GAAP financial measures. Reconciliations to the most directly comparable gap measures are provided in the press release we issued today. Joining me on today's call to deliver prepared remarks and take your questions are Dan Paterson, President and Chief Executive Officer, Dan Lyons, Chief Commercial Officer, and Dr. Michael D. Kauffman, President of Development. And lastly, Dan Calkins, Chief Financial Officer. I will now turn the call over to Dan.
Thank you, Julissa. Good afternoon and thank you for joining our call today. We're encouraged by the progress we've made across our commercial business and the VS-73-75 development program. We generated net product revenue of $24 million in the third quarter with demand holding steady for MAP-Defact-Syngia Copac and strong refills offsetting new patient starts after significant growth in Q2. As Dan Lyons will discuss, we feel that there's still considerable opportunity to be realized for the Copac. While we continue to see a positive impact from the changes we've made throughout the commercial organization, we're making additional efforts to gather feedback from physicians to understand patient experiences and educate on new and existing initiatives. We're also excited to share that our new BlisterPak NDA has been accepted by the FDA with priority review and a PDUFA date of February 2027. This is an important step we're taking to further support patient convenience and adherence to the COPAC. Turning to the VS7375 program, in October, we announced new clinical data from our target D101 trial, including for the first time, U.S. efficacy data and updated safety and tolerability results in KRAS G12D mutated pancreatic, colorectal, and lung cancers. As Michael Kauffman will discuss in more detail, we set a new efficacy benchmark in pancreatic cancer with compelling and confirmed response rates across lines of therapy, and we demonstrated encouraging anti-tumor activity in both colorectal and non-small cell lung cancers. With longer follow-up, VS7375 continued to demonstrate a favorable and manageable safety profile at both the 600 and 900 milligram dose level. Overall, we believe that VS7375 has a potential best-in-class profile and with the recent agreement with the FDA to start our first-line PDAC study, we have an opportunity to bring a chemo-free option to patients with pancreatic cancer. Building on these encouraging VS7375 data, we further strengthened our balance sheet by raising gross proceeds of approximately $250 million in October. Together with our current cash position and expected revenues from the Abhmatke-Faksinja COPAC, the financing proceeds are expected to fund operations across our broad clinical development plans into the first half of 2028. This funding supports our opportunity to expedite the development pathway for VS-7375 phase two trial readouts and initiation of three phase three trials, including our phase three PDAC trial. We look forward to advancing parallel development paths in pancreatic, colorectal and lung cancers with multiple opportunities to create value along the way. Lastly, in October, we announced that I'll be stepping down as president and CEO at the end of 2026 with Michael Bailey, current Veristem board member, stepping into the role. This transition follows my planned retirement, though I'll continue serving on the company's board of directors and as an advisor. Michael is an accomplished biopharmaceutical executive and brings a wealth of experience in oncology drug development and commercialization experience. Most recently, Michael served as president and CEO of Aveo Pharmaceuticals, leading the organization to their acquisition by LG Chem and subsequently led the integrated company through June of this year. Michael will be an important leader through Veristem's next phase of commercial growth, clinical advancement, and operational execution. I'm extremely proud of all that we've accomplished in my 15 years at Veristem. Our work has benefited patients, physicians, families, and the broader healthcare system, and I have great confidence it will continue to make positive impact with our promising future ahead. With that, I'll turn the call over to Dan Lyons for our commercial update. Dan?
You're reading a preview of the VSTM Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing